Mylan’s protracted $12bn merger with Pfizer’s Upjohn off-patent and mature brands unit has today completed, bringing the curtain down on Mylan after nearly six decades of operations and launching a new global player, Viatris.
Viatris Plots ‘Significant’ Restructuring As Mylan-Upjohn Merger Completes
New Company Aims To Achieve $1bn Of Synergies Through Restructuring
Nearly 16 months after it was first announced, the $12bn merger of Mylan and Pfizer’s Upjohn has completed, with the resulting company Viatris preparing to unveil restructuring plans by the end of 2020.
